Identification of Gene Markers for Formaldehyde Exposure in Humans

Guang-Yong Li,¹ Hye-Young Lee,¹ Ho-Sang Shin,² Hyeon-Young Kim,³ Cheol-Hong Lim,³ and Byung-Hoon Lee¹

¹College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea;
²Department of Environmental Education and Abuse Drug Research Center, Kongju National University, Kongju, Republic of Korea;
³Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency, Daejeon, Republic of Korea

BACKGROUND: Formaldehyde (FA) is classified as a human carcinogen and has been linked to increased leukemia rates in some epidemiologic studies. Inhalation of FA induces sensory irritation at relatively low concentrations. However, little is known concerning the cellular alterations observed after FA exposure in humans.

OBJECTIVES: Our aim was to profile global gene expression in Hs 680.Tr human tracheal fibroblasts exposed to FA and to develop biomarkers for the evaluation of FA exposure in humans.

METHODS AND RESULTS: We used gene expression analysis, and identified 54 genes designated as FA responsive. On the basis of these data, we conducted an exploratory analysis of the expression of these genes in human subjects exposed to high or low levels of FA. We monitored FA exposure by measuring the urinary concentration of thiazolidine-4-carboxylate (TZCA), a stable and quantitative cysteinyl adduct of FA. Nine genes were selected for real-time PCR analysis; of these, *BHLHB2, CCNL1, SE20-4, C8FW, PLK2*, and *SGK* showed elevated expression in subjects with high concentrations of TZCA.

CONCLUSION: The identification of gene marker candidates *in vitro* using microarray analysis and their validation using human samples obtained from exposed subjects is a good tool for discovering genes of potential mechanistic interest and biomarkers of exposure. Thus, these genes are differentially expressed in response to FA and are potential effect biomarkers of FA exposure.

KEY WORDS: biomarker, carcinogenesis, formaldehyde, human study, microarray, toxicogenomics. *Environ Health Perspect* 115:1460–1466 (2007). doi:10.1289/ehp.10180 available via *http://dx.doi.org/* [Online 12 July 2007]

Formaldehyde (FA) is an industrial chemical used for manufacturing building materials and household products. It is also found in automobile emissions and tobacco smoke. Inhalation of FA induces sensory irritation at relatively low concentrations in experimental animals as well as in humans (Alexandersson and Hedenstierna 1988; Kane and Alarie 1977). Although animal studies investigating the genotoxic potential of FA did not generate definitive results (Dallas et al. 1992; Migliore et al. 1989), FA is carcinogenic at the site of contact as a consequence of epithelial cell regenerative proliferation resulting from cytotoxicity and mutation (reviewed by Naya and Nakanishi 2005). In 2004 the International Agency for Research on Cancer (IARC) concluded that FA is a known human carcinogen based on sufficient evidence in humans and experimental animals (IARC 2004).

Sick building syndrome (SBS) is the suite of adverse health effects caused by serious indoor air quality problems in homes, offices, and other work places. The syndrome is generally characterized by mucosal irritation and nonspecific hypersensitivity. Although the specific cause of the syndrome has not been identified, the accumulation of chemical and biological contaminants from indoor sources because of inadequate ventilation is regarded as the main factor inducing SBS. Along with many other factors, exposure to FA indoors could contribute to the syndrome. It has been suggested that the recent increase in allergic diseases such as asthma and allergic rhinitis is related to exposure to environmental pollutants such as FA (Takafuji and Nakagawa 2000).

FA is metabolized into formic acid by aldehyde dehydrogenase, which is further oxidized to carbon dioxide or may serve as a one-carbon donor in tetrahydrofolate-dependent synthesis of purine, pyrimidine, and amino acids. Because of its rapid metabolism and exhalation, however, exposure to FA does not always result in an increased blood or urine concentration of parent compound in animals or humans (Gottschling et al. 1984; Heck et al. 1985). Therefore, the development of biomarkers for FA exposure and toxicity is necessary for risk assessment. Thiazolidine-4-carboxylate (TZCA) is formed by a nonenzymatic condensation reaction of L-cysteine with a variety of aminederived aldehydes or carbonyl compounds, including FA (Ratner and Clarke 1937). We recently found that the urinary concentration of TZCA reflects the degree of FA exposure very well (Shin et al., in press). Therefore, we measured the urinary concentration of TZCA as a marker for FA exposure.

The identification of differentially expressed genes or patterns of gene expression using a microarray hybridization assay provides a logical approach to developing potential biomarkers of toxicity. Hundreds of publications have suggested the use of biomarkers for the diagnosis and prognosis of disease, as well as for the assessment of exposure to xenobiotics in cells and animal tissues. However, only a very limited number of candidate gene markers can ultimately be used in human samples. The reasons for this include the inaccuracy of microarray data, discrepancies among in vitro, in vivo, and human studies, and the lack of validation of the in vitro or in vivo data in human samples. To this end, we investigated the effects of FA on gene expression in human tracheal fibroblast and validated the results in human samples with varying degrees of FA exposure. Our overall goal was to identify global changes in gene expression following FA exposure to produce mechanistic insight into FA-induced toxicity and to provide potential biomarkers that can be used in risk assessment for FA exposure.

Materials and Methods

Cells and chemicals. The Hs 680.Tr human tracheal fibroblast cell line was maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) in a 5% CO_2 atmosphere at 37°C. The culture medium does not contain cysteine. FA, TZCA, and 2-methyl-TZCA were purchased from Sigma Chemical Co. (St. Louis, MO, USA).

Cell viability measurement. We incubated the cells with various concentrations $(0, 20, 50, 100, \text{ and } 200 \ \mu\text{M})$ of FA for 4 and 24 hr. Aqueous solution of FA (37%) was added directly to the incubation media. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay.

RNA isolation. Total RNA was extracted using an Easy-Blue total RNA extraction kit (Intron Biotech, Sungnam, Korea), purified using Qiagen RNeasy Mini Kits (Qiagen, Basel, Switzerland), and examined for integrity using an Agilent 2100 Bioanalyzer (Ambion, Austin, TX, USA).

Address correspondence to B-H. Lee, College of Pharmacy, Seoul National University, San 56-1, Sillim-dong, Gwanak-gu, Seoul 151-742, Republic of Korea. Telephone: +82-2-880-7843. Fax: +82-2-874-7843. E-mail: lee@snu.ac.kr

Supplemental Material is available online (http:// www.ehponline.org/docs/2007/10180/suppl.pdf).

This work was supported by the Ministry of Environment as "The Eco-Technopia 21 Project."

The authors declare they have no competing financial interests.

Received 20 February 2007; accepted 12 July 2007.

Microarray hybridization and data analysis. To analyze differential gene expression profiles, we used Sentrix HumanRef-8 Expression BeadChips (Illumina, San Diego, CA, USA) containing more than 23,000 genes. A detailed description of the BeadChip system has been provided elsewhere (Kuhn et al. 2004). Briefly, biotinylated cRNA was prepared and linearly amplified from 1.5 µg of total RNA using an Illumina RNA Amplification kit (Ambion) and purified using the Qiagen RNeasy kit (Qiagen). Hybridization, washing, and scanning were performed according to the Illumina BeadStation 500 manual (Kuhn et al. 2004). The quality of hybridization and overall chip performance were monitored by visual inspection of both internal quality control checks and the raw scanned data. Data were filtered by the detection score, which is 1 minus the *p*-value computed from the background model, characterizing the chance that the target sequence signal was distinguishable from the negative controls. A total of 15,262 probes had a detection score that was greater than the average score in more than four of eight measurements, and these probes were analyzed further. Data were extracted using the software provided by the manufacturer (BeadStudio, version 1.0.0.5) and subjected to quantile normalization. One-way analysis of variance (ANOVA) and Tukey's HSD test were applied to distinguish differentially expressed sets of genes across the three experimental groups. Statistical significances were adjusted by the Benjamini-Hochberg FDR multiple-testing correction. Hierarchical clustering was performed using the Euclidean method. Biological pathway and ontology-based analyses were performed using GenMAPP software (Gene Map Annotator and Pathway Profiler 2007) and the PANTHER database (PANTHER Classification System 2007).

Quantitative real-time reverse transcriptase polymerase chain reaction. Total RNA was purified using the Easy-Blue Total RNA Extraction Kit (Intron Biotech, Korea) and then used to synthesize single-strand cDNA in a reaction mixture containing random hexamers and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Gene-specific primers (Table 1) were designed using Oligo 6.0 software (Molecular Biology Insights, Cascade, CO, USA). Quantitative real-time reverse transcription-polymerase chain reaction (Q-PCR) was performed using a Fast Start DNA Master SYBR Green I mixture kit (Roche Diagnostics, Indianapolis, IN, USA) in a Light Cycler system (Roche Diagnostics) according to the manufacturer's protocol. To confirm the specificity of amplification, we applied melting-curve analysis to all final PCR products.

Study subjects. The study was approved by the institutional review board at the College of Pharmacy, Seoul National University, and written informed consent was obtained from each subject. The study subjects consisted of 109 residents who had been living for more than 2 weeks in new apartments built at the end of 2005 (high-exposure group) and 20 control subjects who had been living in older apartments built between 1981 and 1985 (low-exposure group). We evaluated FA exposure by measuring the urinary concentration of TZCA, a stable and quantitative cysteinyl adduct of formaldehyde (Ratner and Clarke, 1937). Among residents whose urinary TZCA concentrations were higher than the mean TZCA concentration of the low-exposure group $(0.097 \pm 0.040 \text{ mg/g creatinine})$, 17 subjects were enrolled in the main study. Seven control subjects whose TZCA concentrations were lower than the mean of the lowexposure group were also included. Overnight urine and 20 mL of whole blood were collected and processed immediately. Initial clinical investigations were performed. Blood samples were mixed with RNA later (Ambion) and stored at -80°C until use. After RNA purification, a total of 22 samples had RNA quality that was suitable for Q-PCR. Because of the lack of the statistically significant difference in the TZCA concentrations between the two groups, all samples were further divided into groups on the basis of the urinary concentration of TZCA.

Extraction of TZCA from urine. In a 15-mL test tube, 1.0 mL of urine sample was placed. About 150 mg of ethylchloroformate, 1.5 mL of methanol/pyridine solution (4/1, vol/vol) and d⁴-2-methyl-TZCA internal standard solution (2.0 μ L/mL in water) were added to the solution, and the sample was extracted with 3 mL of toluene by mechanical shaking for 20 min. The organic phase was dried to 0.1 mL under a nitrogen stream.

Measurement of the urinary concentration of TZCA. Samples were injected into the

| | Table 1. Gene-s | pecific | primers | used | in | Q-PCR |
|--|-----------------|---------|---------|------|----|-------|
|--|-----------------|---------|---------|------|----|-------|

gas chromatography (GC) system in split mode at a split ratio of 1:10. All mass spectra were obtained with an Agilent 6890/5973 N instrument using the electron ionization mode (EI; 70 eV, 150°C; Agilent). Full-scan mass spectra (m/z 40-450) were recorded for analyte identification. Helium was used as a carrier gas at a flow rate of 0.9 mL/min. The GC operating temperatures were injector temperature, 240°C; transfer line temperature, 280°C; oven temperature, programmed to rise from 80°C to 240°C at 10°C/min (held for 3 min). The ions selected for quantification by selective ion monitoring (SIM) were m/z 178 and 151 for d4-m-TZCA (internal standard), m/z 174 and 147 for m-TZCA, and m/z 160 and 133 for TZCA. Calibration curves for TZCA and m-TZCA were established by extraction and derivatization after adding 20, 40, 100, 200, and 400 ng of standards and 200 ng of internal standard to 1.0 mL of urine. The ratio of the peak area of standard to that of internal standard was used to quantify the compound.

Statistical analysis. We used Graphpad PRISM Software (San Diego, CA, USA) to analyze the data. Differences between groups were analyzed using one-way ANOVA followed by Tukey's multiple comparisons or using *t*-tests. The relative gene expression changes were expressed as the fold change using the $2-\Delta\Delta CT$ method (Livak and Schmittgen 2001). Statistical significance of the fold change in gene expression between control and exposure groups was analyzed using t-tests. The correlation between changes in gene expression (fold change) and TZCA level was expressed as a Pearson coefficient of correlation. The level of significance for all analyses was set at 0.05.

Results

Identification of FA-responsive genes in Hs 680. Tr cells. To establish an optimal concentration of FA for microarray analysis, we incubated Hs 680. Tr cells with media

| Gene | NCBI RefSeq ^a | Forward primer (5´-3´) | Reverse primer (5´-3´) |
|----------|--------------------------|-------------------------|--------------------------|
| PLK2 | NM_006622 | AGTTGTCAGCCTGAAAGTTGTAG | CTGATAAGGCCCTAATGATGCTC |
| SGK | NM_005627 | TGAACTTCAGGGTGTTTGCAT | ATGACGGTGAAAACTGAGGCT |
| SE20-4 | NM_022117 | ACAGGTGCTGGCCGATATG | CCGACTCGATGGTAGAATCCC |
| BHLHB2 | NM_003670 | TGGTGAGCTGTCAGGGAGAAT | GACAAGCTGCGAAGACTTCAGG |
| CCNL1 | NM_020307 | TGCAGTCACAGTGAAAGCCCT | CGACTTGCTCTGAGATCGAGAAC |
| C8FW | NM_020307 | GTTGGGGACATGCACTCCTATG | ACGTGGAGAAGACGAACTTCCTAA |
| HES1 | NM_005524 | GACAGGTGCTGGCCGATATG | TTTCAGAGCATCCAAAATCAGTGT |
| FOSB | NM_006732 | AGCAGCAGCTAAATGCAGGA | TTTTGGAGCTCGGCGATCT |
| DUSP2 | NM_004418 | TTTTCCGCTACAAGAGTATCCC | GCCCACCAGTCCACAGTCAG |
| PPP1R15A | NM_014330 | TCCTCTGGCAATCCCCCATA | GGAACTGCTGGTTTTCAGCC |
| NFKBIA | NM_020529 | CTCCGAGACTTTCGAGGAAATAC | GCCATTGTAGTTGGTAGCCTTCA |
| NEU1 | NM_000434 | CTTTGCTGAGGCGAGGAAAAT | CAATGAACGCTGTAGGAGACC |
| DDAH1 | NM_012137 | TTAGATGGCGGAGATGTTT | TTGTCGTAGCGGTGGTC |
| NFATC1 | NM_172390 | AAGAAGATGGTCCTGTCTGGC | TTATCCTCTGATTCCGAAATGG |
| NFKB1 | NM_003998 | GATTTCGTTTCCGTTATG | CCTTGGGTCCAGCAGTT |

^aFrom the National Center for Biotechnology Information (NCBI), Entrez Nucleotide database (NCBI 2006a).

containing FA (0, 20, 50, 100, and 200 µM) and then determined cell viability using the MTT colorimetric assay. The concentrations of FA that induced the half-maximal cytotoxic effect (IC₅₀) were 99.6 \pm 1.1 μ M at 4 hr and 69.0 \pm 1.1 μ M at 24 hr (Figure 1). To minimize the fixative effect of FA, which increases with concentration and time, we analyzed changes in gene expression after 4 hr of incubation with either 10 or 100 μ M FA. Illumina gene expression arrays containing more than 23,000 oligonucleotide probes were used to analyze global gene expression in duplicate control and triplicate FA-treated Hs 680.Tr cells. Technical replicates had a very high reproducibility, with correlation coefficients of 0.92. One-way ANOVA (p < 0.05), Tukey's HSD test (p < 0.05), and Benjamini-Hochberg data correction of control and FA-treated cells identified 1,369 genes [see Supplemental Material (http://www.ehponline.org/docs/ 2007/1018/suppl.pdf)].

Functional categorization of the data was performed using annotation information in the PANTHER database for ontology (PANTHER Classification System 2007). FA-induced changes in gene expression are involved in a variety of biological processes. The largest group of affected genes was associated with nucleoside, nucleotide, and nucleic acid metabolism, whereas genes related to signal transduction, protein metabolism, and developmental processes were the next most abundant annotation groups. Dendrogram tree analysis of the genes showed patterns responsive to the treatment conditions (Figure 2).

When the data were filtered for a 2-fold difference in expression level and a coefficient of variation (CV) < 0.02, 54 FA-responsive genes were extracted (Table 2). Genes without clear annotations, for example, expressed




Figure 1. Acute cytotoxicity of formaldehyde (FA) in Hs 680.Tr human tracheal fibroblasts. The cells were incubated with increasing concentrations of FA in medium containing 10% fetal bovine serum for 4 and 24 hr, after which viability was determined by MTT assay. Results are expressed as the percent of viable cells compared with solvent control.

sequence tags, were excluded from the table. However, FA-responsive genes are not limited to these 54 genes but include all the 1,369 genes identified by the one-way ANOVA, Tukey's HSD test, and Benjamini-Hochberg correction.

Validation of gene expression in Hs 680.Tr cells by Q-PCR. We performed Q-PCR to validate the microarray data. We selected genes for Q-PCR on the basis of the magnitude and direction (+/–) of gene expression from each of the categories in Table 2, namely, signal transduction, apoptosis, cell proliferation and differentiation, cell cycle, developmental process, immunity and defense, and intracellular protein traffic. We selected 15 of the




Figure 2. Hierarchical cluster analysis of differentially expressed genes altered more than 2-fold in formaldehyde-treated Hs 680.Tr cells. Cont, control. The analysis was performed using 54 genes obtained by adjustment of the data using the Benjamini-Hochberg multiple test correction. Red and green colors in the matrix indicate the relative gene induction and repression, respectively. The dendrogram groups genes according to overall similarities in the gene expression profile. 54 genes for Q-PCR analysis; these included 12 genes showing increased expression and 3 genes showing down-regulation in all groups of FA-treated cells. Of all the genes analyzed with Q-PCR, only *PPP1R15A*, *NFKB1A*, and *NEU1* expression differed from the microarray results. However, in most cases, there was good correlation between the microarray analysis and Q-PCR (Table 3).

Characteristics of study subjects used for validation of the candidate gene markers. After demonstrating close agreement between the two quantification methods for the expression of genes listed in Table 3, we analyzed their expression in FA-exposed and control subjects using Q-PCR. In the first screening experiment, 109 new- and 20 oldapartment residents were recruited, representing high- and low-exposure subjects, respectively, and urine samples were collected for the measurement of TZCA. The mean concentration of TZCA in the low-exposure group was 0.097 ± 0.04 mg/g creatinine, whereas the mean of the high-exposure group was 85.6% higher (0.180 ± 0.121 mg/g creatinine; p < 0.003). All study subjects were Korean and the demographic data are summarized in Table 4. The age of subjects and number of smokers were comparable between the exposed and control groups. We then further subdivided the test subjects. From the exposed residents whose urinary TZCA concentrations were higher than the mean TZCA concentration of the low-exposure group, 17 subjects were enrolled in the second experiment to analyze gene expression. Seven of the control subjects whose TZCA concentrations were lower than the mean of the low-exposure group were also included. However, 22 samples that had RNA quality suitable for Q-PCR were further analyzed.

Effects of FA exposure on expression of the differentially expressed genes. In the second experiment, whole blood and urine samples obtained from the subjects were analyzed by Q-PCR for the expression of the selected genes and by GC-MS for urinary excretion of TZCA (Table 5). Because of the lack of significant difference in TZCA concentration between the control and exposed groups, we reclassified the subjects into three groups according to the urinary concentration of TZCA. The low-TZCA group, representing the lower 25% in TZCA concentration in all test subjects, comprised subjects with TZCA concentrations lower than 0.053 mg/g creatinine. The intermediate- (between 0.053 and 0.141 mg/g creatinine) and high-TZCA groups (higher than 0.141 mg/g creatinine) contained the subjects whose TZCA concentrations ranked the next 50% and the last 25% in all the test subjects. Demographics details of the subjects in the second experiments are listed in Table 5. We found no

VOLUME 115 | NUMBER 10 | October 2007 • Environmental Health Perspectives

| statistically significant differences in the dis- tribution of age between groups. No smokers participated in this study. The expression of most genes tested showed good correlation with FA exposure (Figure 3); of these, <i>BHLHB2, CCNL1, SE20-4, C8FW, PLK2,</i> and <i>SGK</i> were the most significantly altered. For <i>BHLHB2, CCNL1,</i> and <i>SGK</i> , gene expression increased in a TZCA concentra- tion-dependent manner, and the changes were statistically significant between the intermediate- and low-TZCA groups and between the high- and low-TZCA groups. In contrast, <i>SE20-4, C8FW,</i> and <i>PLK2</i> showed significance only between the high- and low- TZCA groups. Correlation analysis showed that urinary TZCA concentrations were closely correlated with gene expression for <i>C8FW</i> and <i>SGK.</i> Another four genes showed weak-to-moderate correlation with TZCA |
|--|
| weak-to-moderate correlation with TZCA |
| level (Figure 4). Thus, these 6 genes are dif- ferentially expressed following FA exposure in humans and have the potential to be devel- oped as FA biomarkers. |

Discussion

FA is an environmental contaminant that warrants concern for human health. Longterm exposure to FA is closely associated with adverse health effects ranging from irritation and inflammation (Alexandersson and Hedenstierna 1988; Kane and Alarie 1977) to squamous cell carcinomas in the nasal cavities (Kerns et al. 1983), depending on the concentration and duration of exposure. Animal and human studies have not shown clear results with regard to the genotoxic potential of FA. Evaluation of the available data indicates that FA is genotoxic in vitro (Speit and Merk 2002), although it is not generally genotoxic in standard in vivo assays (Speit et al. 2007). The carcinogenic effect of FA is caused by prolonged regenerative cell proliferation associated with its cytotoxicity, which increases the number of DNA replications and thus increases the probability of DNA-protein cross-link (DPX)-initiated replication errors (Liteplo and Meek 2003; Speit et al. 2000).

Because of its high chemical reactivity, individuals exposed to low concentrations of FA did not show any significant differences in the blood concentration of FA or urinary concentration of formic acid compared with controls (Gottschling et al. 1984). For this reason the reaction of FA with macromolecules and the formation of DPX in peripheral blood lymphocytes have been used as surrogate measures for FA exposure (Shaham et al. 2003). However, DPX is not a specific biomarker for FA; it also forms after exposure to many other environmental chemicals or ionizing radiation (Al-Nabulsi and Wheeler 1999; Chakrabarti et al. 2001).

| NM_025217.1 SE20-4 0.004 0.000 4.0 0.01 Carbolydrate metabolism | GenBank accession no.ª | Gene symbol | ANOVA (<i>p</i> -Value) | <i>t</i> -Test (<i>p</i> -Value) | Fold change (100 µM) | СV ^ь (0 µМ) | CV (100 μM) |
|---|----------------------------|-------------|-----------------------------|--------------------------------------|-------------------------|---------------------------|----------------|
| NM_0123012 PPP1P15A 0.0005 0.0000 4.6 0.000 0.00 NM_020572 SGK 0.0013 0.0000 4.0 0.01 0.0 Carobydrate metabolism 0.0000 -3.2 0.02 0.0 Carobydrate metabolism 0.0000 -3.2 0.02 0.0 Carobydrate metabolism 0.0000 -3.2 0.02 0.0 Carobydrate metabolism 0.0000 -3.2 0.00 0.0 Carobydrate metabolism 0.000 -3.2 0.00 0.0 NM_056313 MA4P 0.0022 0.0000 2.0 0.0 0.0 NM_005732.1 FOSB 0.0000 0.0000 52.0 0.01 0.0 NM_005732.3 JUN 0.0122 0.0001 7.0 0.0 0.0 NM_005782.3 JUN 0.0110 0.0000 7.9 0.00 0.0 NM_005782.4 <td>Apoptosis</td> <td>· · · · ·</td> <td></td> <td></td> <td></td> <td>· ·</td> <td></td> | Apoptosis | · · · · · | | | | · · | |
| NML 005627.2 SEK 0.013 0.0000 4.0 0.011 0.02 NML 005328.1 HAS2 0.0022 0.0000 -3.2 0.02 0.0 NML 005328.1 VCAM1 0.0022 0.0000 -4.6 0.02 0.0 Call adhesio 0.011 0.0 0.00 -4.6 0.02 0.00 Call adhesio 0.011 0.0 0.00 | | PPP1R15A | 0.0006 | 0.0000 | 4.6 | 0.00 | 0.01 |
| Carbinydrate metabolism | - | | | | | | 0.01 |
| NML 005328.1 HAS2 0.0008 0.0000 -3.2 0.02 0.00 NML 005082.1 VCAM1 0.0022 0.0000 -4.6 0.02 0.0 Cell adhesion | - | SGK | 0.0013 | 0.0000 | 4.0 | 0.01 | 0.00 |
| NN_02006082.1 VCAM1 0.002 0.000 -4.6 0.02 0.00 NM_153742.3 CTH 0.0048 0.0001 2.1 0.01 0.0 Cell adhesion 0.01 0.02 0.00 0.00 NM_020307.1 CCNL1 0.0038 0.0000 2.2 0.01 0.0 NM_005461.3 MAHB 0.0022 0.0000 4.9 0.00 0.00 NM_000673.1 CDNNC 0.0022 0.0001 7.0 0.01 0.0 NM_00075.1 CDNNC 0.0022 0.0001 7.0 0.0 0.0 NM_00515.2 ACTC 0.0015 0.0000 -2.9 0.01 0.0 NM_00515.2 ACTC 0.0101 0.0000 -2.2 0.01 0.0 NM_017137.2 DDAH1 0.010 0.0000 -2.3 0.01 0.0 NM_00393.2 EGR2 0.001 0.000 2.3 0.01 0.0 NM_000554.2 <t< td=""><td></td><td>114.02</td><td>0.0000</td><td>0.0000</td><td>0.0</td><td>0.02</td><td>0.00</td></t<> | | 114.02 | 0.0000 | 0.0000 | 0.0 | 0.02 | 0.00 |
| Cell adhesion VIM_153742.3 CTH 0.0048 0.0001 2.1 0.01 0.0 Cell cycle VIM_021459.3 SESN2 0.002 0.0000 4.9 0.00 0.0 NM_005752.1 F/SB 0.0001 3.2 0.00 0.00 NM_00572.1 F/SB 0.0001 3.6 0.01 0.0 NM_005763.2 BTG2 0.0001 0.0000 7.9 0.00 0.00 NM_005763.2 BTG2 0.0010 0.0000 -2.9 0.01 0.0 NM_005763.3 PAPA 0.0025 0.0001 -2.1 0.00 0.00 NM_005763.3 PAPA 0.0020 0.000 2.01 0.00 0.00 0.00 | - | | | | | | |
| INM_152742.3 CTH 0.0048 0.0001 2.1 0.01 0.0 Cell cycle | | VUAIVIT | 0.0022 | 0.0000 | -4.0 | 0.02 | 0.02 |
| Cell cycle VIII CCNL1 0.0038 0.0001 3.2 0.00 0.0 NM_031493 SESN/2 0.0023 0.0000 4.9 0.00 0.00 NM_005461.3 MAFB 0.0002 0.0000 4.9 0.00 0.00 NM_00572.1 F05B 0.0000 2.6 0.00 | | CTH | 0.0048 | 0.0001 | 2.1 | 0.01 | 0.00 |
| NM_0031459.3 SESN2 0.0023 0.0000 2.2 0.01 0.0 NM_005742.1 FOSB 0.0001 0.0000 2.6 0.00 0.00 NM_005732.1 FOSB 0.0001 0.0000 2.6 0.00 0.00 NM_000751. CDKN1C 0.0022 0.0001 0.000 7.9 0.01 0.00 NM_005751. CDKN1C 0.0012 0.0000 7.9 0.00 0.00 NM_005159.2 ACTC 0.0010 0.0000 -2.6 0.00 0.00 NM_012137.2 DDAH1 0.0110 0.0000 -2.6 0.00 0.00 NM_00357.1 BHLHB2 0.0014 0.0000 2.8 0.01 0.00 Developmental processes NM_00339.2 EGR2 0.0001 0.000 1.9 0.1 0.0 NM_00327.3 AGC1491 0.0020 0.000 2.3 0.01 0.0 NM_00328.2 EGR2 0.0001 0.0000 | _ | | | | | | |
| NNL_005732.1 FOSB 0.0000 4.9 0.00 0.00 NM_002732.1 FOSB 0.0000 0.0000 52.0 0.01 0.0 NM_000761.1 CDKN1C 0.0022 0.001 3.6 0.01 0.0 NM_00418.2 DUSP2 0.0001 0.000 7.9 0.00 0.0 NM_005159.2 ACTC 0.0015 0.0000 -2.9 0.01 0.0 NM_017137.7 FABGAP1 0.0025 0.0001 -2.1 0.00 0.0 NM_02581.3 FAPPA 0.0025 0.0001 -2.1 0.00 0.0 NM_005574.2 HES1 0.0103 0.0000 2.8 0.01 0.0 Developmental processes NM_00539.3 0.02 0.00 NM_00239.2 EGR2 0.001 0.000 2.3 0.0 0.0 NM_00339.2 EGR2 0.001 0.0000 2.3 0.0 0.0 NM_00339.3 AGC1497 0.0022 0.0000 2.0 | NM_020307.1 | CCNL1 | 0.0038 | 0.0001 | 3.2 | 0.00 | 0.01 |
| NN_0007321 FOSB 0.0000 52.0 0.01 0.0 NM_0000761 CDKN1C 0.0001 2.6 0.00 0.00 NM_0000761 CDKN1C 0.002 0.000 17.0 0.01 0.00 NM_0007632 BTG2 0.0001 0.0000 -2.9 0.01 0.00 NM_005159.2 ACTC 0.0010 0.0000 -2.6 0.00 0.00 NM_0025159.2 ACTC 0.0011 0.0000 -2.6 0.00 0.00 NM_002513.3 PAPPA 0.0012 0.000 -2.1 0.01 0.00 Cell proliferation and differentiation NM 0.00570.1 BHLHB2 0.001 0.0000 15.9 0.01 0.00 NM_005254.2 HES1 0.0020 0.0000 2.3 0.00 0.00 NM_01753.1 CGar37 0.004 0.0000 -2.3 0.00 0.00 NM_01755.3 HSPA6 0.0000 -2.5 0.00 0.00 NM_022 | | | | | | | 0.01 |
| NN_002228.3 JUN 0.0014 0.0000 2.6 0.00 0.0 NN_004418.2 DUSP2 0.0001 3.6 0.01 0.0 NM_004418.2 DUSP2 0.0001 0.0000 7.9 0.00 0.00 NM_005159.2 ACTC 0.0011 0.0000 -2.6 0.00 0.00 NM_002581.3 PAPPA 0.0025 0.0001 -2.1 0.00 0.00 Cell proliferation and differentiation NM_017137.2 DDAH1 0.010 0.0000 2.8 0.01 0.00 Cell proliferation and differentiation NM_005524.2 HES1 0.0001 0.0000 2.3 0.01 0.00 NM_005594.2 HES1 0.0002 0.0000 2.3 0.01 0.00 NM_017258.2 HEY1 0.0022 0.0000 2.3 0.00 0.00 NM_02593.1 Ceord37 0.0000 0.0000 2.2 0.02 0.00 NM_002135.3 HEY1 0.0022 0.000 0.0 | | | | | | | 0.00 |
| NN_000076.1 CDKN1C 0.0022 0.0001 3.6 0.01 0.0 NM_00076.1 DUSP2 0.0001 0.0000 7.9 0.00 0.00 NM_00076.3 BT62 0.0015 0.0000 -2.9 0.01 0.0 NM_002581.3 PAPPA 0.0025 0.0001 -2.1 0.00 0.0 NM_002581.3 PAPA 0.0025 0.0001 -2.2 0.01 0.00 Cell proliferation and differentiation NM 0.00270.1 BHLHB2 0.0014 0.0000 2.8 0.01 0.00 NM_00359.2 EGR2 0.0011 0.0000 15.9 0.01 0.00 NM_01258.2 HEY1 0.0022 0.0000 2.3 0.00 0.00 NM_02529.3.1 CBGR73 0.004 0.0000 2.3 0.00 0.00 NM_02175.3 AGC1 0.0080 0.0001 -2.5 0.01 0.00 NM_02173.1 NRA42 0.0000 0.0000 4.4 | — | | | | | | 0.00 |
| NN_000763.2 DUSP2 0.0001 0.0000 17.0 0.01 0.00 NM_000763.2 BTG2 0.0003 0.0000 -7.9 0.00 0.0 NM_0005159.2 ACTC 0.0010 0.0000 -2.6 0.00 0.0 NM_002581.3 PAPPA 0.0025 0.0001 -2.1 0.00 0.0 NM_00370.1 BHLHB2 0.0014 0.0000 -2.8 0.01 0.00 Developmental processes NM_00370.1 BHLHB2 0.001 0.000 2.3 0.01 0.00 NM_00399.2 EGR2 0.001 0.0000 2.3 0.00 0.0 NM_011258.2 HEY1 0.0020 0.0000 2.3 0.00 0.0 NM_011258.1 AGC1 0.0000 0.000 2.3 0.00 0.0 NM_02135.1 AGC1 0.0000 0.0003 -2.5 0.00 0.0 NM_0232827.3 ATOH8 0.0159 0.0016 -2.2 0.02 | — | | | | | | 0.01 |
| NN_006763.2 BTG2 0.0003 0.0000 7.9 0.00 0.00 NM_012187.2 ACTC 0.0015 0.0000 -2.6 0.00 0.00 NM_012187.2 DDAH1 0.0110 0.0000 -2.6 0.00 0.00 NM_012187.2 DDAH1 0.0110 0.0000 -2.8 0.01 0.0 Cell proliferation and differentiation | — | | | | | | 0.01 |
| NN_012197.2 RABGAP1 0.0010 0.0000 -2.6 0.00 0.0 NN_002381.3 PAPPA 0.0025 0.0001 -2.1 0.00 0.0 NM_012137.2 DDAH1 0.0110 0.0008 -2.2 0.01 0.0 Cell proliferation and differentiation 0.0000 2.8 0.01 0.0 Developmental processes 0.0000 8.9 0.02 0.0 NM_00339.2 EGR2 0.001 0.0000 2.3 0.01 0.0 NM_011258.2 HEY1 0.0022 0.0000 2.3 0.00 0.0 NM_01135.1 AGC173 0.0040 0.0000 -2.2 0.00 0.0 Immunity and defense NM 0.0159 0.016 -2.2 0.00 0.0 NM_002154.2 FRP4 0.0000 0.0000 4.4 0.00 0.0 NM 0.01 0.0 0.0 NM 0.00 0.0 | - | | | | | | 0.00 |
| NN_02581.3 PAPPA 0.0025 0.001 -2.1 0.00 0.0 NM_012137.2 DDAH1 0.0110 0.0008 -2.2 0.01 0.0 Cell proliferation and differentiation | NM_005159.2 | ACTC | 0.0015 | 0.0000 | -2.9 | 0.01 | 0.00 |
| NM_012137.2 DDAH1 0.0110 0.0008 2.2 0.01 0.0 Cell proliferation and differentiation | - | | | | | | 0.00 |
| Cell proliferation and differentiation 0.0014 0.0000 2.8 0.01 0.0 NM_003670.1 BHLIBZ 0.0003 0.0000 8.9 0.02 0.0 NM_005524.2 HES1 0.0001 0.0000 8.9 0.02 0.0 NM_05294.2 HES1 0.0022 0.0000 2.3 0.01 0.0 NM_012258.2 HEY1 0.0022 0.0000 2.3 0.01 0.0 NM_017135.1 AGC1 0.0080 0.0003 -2.5 0.00 0.0 NM_0232827.3 ATOH8 0.0159 0.0016 -2.2 0.02 0.00 NM_020214.2 FKBP4 0.0003 0.0000 2.8 0.00 0.0 NM_00252.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_00398.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.0 NM_00399.2 NFKB1 0.0003 0.0000 -2.8 0.01 0.0 NM_00399 | _ | | | | | | 0.01 |
| NM_003670.1 BHLHB2 0.0014 0.0000 2.8 0.01 0.00 Developmental processes | | | 0.0110 | 0.0008 | -2.2 | 0.01 | 0.01 |
| Developmental processes NM0005524.2 HES1 0.0001 0.0000 15.9 0.01 0.00 NM002593.2 EGR2 0.0001 0.0000 2.3 0.01 0.00 NM012258.2 HEY1 0.0022 0.0000 2.3 0.00 0.00 NM017633.1 C6orf37 0.004 0.0000 2.3 0.00 0.00 NM_032827.3 ATOH8 0.0159 0.0016 -2.2 0.02 0.00 NM_002155.3 HSP46 0.0000 0.0000 64.4 0.01 0.00 NM_002552.2 FOS 0.0001 0.0000 4.1 0.00 0.00 NM_005291.2 TINFAIP2 0.0024 0.0000 -2.8 0.00 0.00 NM_005291.2 NFKB1 0.0002 0.000 -2.8 0.00 0.00 NM_003998.2 NFKB1 0.0007 0.0003 2.2 0.02 0.00 NM_004089.2 DSIP 0.0002 0.000 3.8 | | | 0.001/ | 0 0000 | 2.8 | 0.01 | 0.00 |
| NM_005524.2 HES1 0.0003 0.0000 8.9 0.02 0.00 NM_000399.2 EGR2 0.0001 0.0000 15.9 0.01 0.0 NM_052943.2 M6C16491 0.0020 0.0000 2.3 0.01 0.0 NM_012258.2 HEY1 0.0022 0.0000 2.3 0.00 0.0 NM_01135.1 AGC1 0.0080 0.0003 -2.5 0.00 0.0 NM_0221258.3 HSPA6 0.0016 -2.2 0.02 0.0 NM_002155.3 HSPA6 0.0000 0.0000 64.4 0.01 0.0 NM_002552.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_005291.2 TNFAIP2 0.0024 0.0000 -2.8 0.00 0.0 NM_005398.2 NFKB1 0.0003 0.0000 -2.9 0.01 0.0 NM_005491.2 NFKA1 0.0008 0.0000 -2.9 0.01 0.0 NM_005291.2 < | _ | DITLITUZ | 0.0014 | 0.0000 | 2.0 | 0.01 | 0.00 |
| NM_000399.2 EGR2 0.0001 0.0000 15.9 0.01 0.0 NM_0125294.3.2 MGC16491 0.0020 0.0000 2.2 0.02 0.00 NM_017633.1 C6orf37 0.0004 0.0000 2.3 0.00 0.0 NM_017633.1 C6orf37 0.004 0.0003 -2.5 0.00 0.0 NM_0232827.3 ATOH8 0.0159 0.0016 -2.2 0.02 0.0 NM_0232827.3 ATOH8 0.0000 0.0000 2.8 0.00 0.0 NM_002155.3 HSPA6 0.0000 0.0000 2.8 0.00 0.0 NM_002525.2 FOS 0.0001 0.0000 4.1 0.00 0.0 NM_005291.2 TNFAIP2 0.0024 0.0000 -2.8 0.00 0.0 NM_006398.2 NFKB1 0.0003 0.22 0.02 0.0 NM_00643.2 NEU1 0.0079 0.0003 2.2 0.01 0.0 NM_00643.2 | | HES1 | 0.0003 | 0.0000 | 8.9 | 0.02 | 0.01 |
| NM_012258.2 HEY1 0.0022 0.0000 2.2 0.02 0.00 NM_017633.1 C6orf37 0.0004 0.0000 2.3 0.00 0.0 NM_001135.1 AGC1 0.0080 0.0003 -2.5 0.00 0.0 NM_022827.3 AT0H8 0.0159 0.0016 -2.2 0.02 0.00 NM_002155.3 HSPA6 0.0000 0.0000 64.4 0.01 0.00 NM_00214.2 FKBP4 0.0003 0.0000 4.1 0.00 0.0 NM_005252.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_00598.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.0 NM_00699.2 NFKB1 0.0007 0.0000 -2.9 0.01 0.0 NM_001641.2 ARF4L 0.0008 0.0000 3.8 0.01 0.0 NM_001642.1 AFF4L 0.0003 0.0000 3.2 0.02 0.0 NM_000 | | EGR2 | | | | | 0.01 |
| NM_017633.1 C6orf37 0.0004 0.0000 2.3 0.00 0.0 NM_001135.1 AGC1 0.0080 0.0003 -2.5 0.00 0.00 NM_032827.3 ATOH8 0.0159 0.0016 -2.2 0.02 0.00 Immunity and defense | NM_052943.2 | MGC16491 | 0.0020 | 0.0000 | 2.3 | 0.01 | 0.01 |
| NM_001135.1 AGC1 0.0080 0.0003 -2.5 0.00 0.00 NM_032827.3 ATOHB 0.0159 0.0016 -2.2 0.02 0.00 Immunity and defense 0.000 64.4 0.01 0.00 NM_002155.3 HSPA6 0.0000 0.0000 2.8 0.00 0.00 NM_002152.2 FOS 0.0001 0.0000 4.1 0.00 0.00 NM_005252.2 FOS 0.0001 0.0000 -2.8 0.00 0.00 NM_005398.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.00 NM_001661.2 ARF4L 0.0007 0.0000 -2.9 0.01 0.00 NM_001641.2 ARF4L 0.0008 0.0000 3.8 0.01 0.00 NM_001434.2 NEU1 0.0079 0.0003 3.2 0.00 0.00 NM_015001.2 SHARP 0.003 0.0000 3.1 0.00 0.00 <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.01</td> | _ | | | | | | 0.01 |
| NM_032827.3 ATOH8 0.0159 0.0016 2.2 0.02 0.00 Immunity and defense | _ | | | | | | 0.01 |
| Immunity and defense NM_002155.3 HSPA6 0.0000 0.0000 64.4 0.01 0.0 NM_002014.2 FKBP4 0.0003 0.0000 2.8 0.00 0.0 NM_005252.2 FOS 0.0001 0.0000 62.1 0.01 0.0 NM_005252.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_003998.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.0 Intracellular protein traffic NM_001661.2 ARF4L 0.0007 0.0000 3.8 0.01 0.0 NM_001661.2 ARF4L 0.0006 0.0000 6.2 0.01 0.0 NM_031419.1 MAIL 0.0003 0.0001 -2.2 | _ | | | | | | 0.02 |
| NM_002155.3 HSPA6 0.0000 0.0000 64.4 0.01 0.0 NM_002014.2 FKBP4 0.0003 0.0000 2.8 0.00 0.0 NM_173173.1 NR4A2 0.0000 0.0000 4.1 0.00 0.0 NM_005252.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_005291.2 TNFAIP2 0.0024 0.0000 -2.5 0.01 0.0 NM_005291.2 TNFAIP2 0.0027 0.0000 -2.8 0.00 0.0 NM_00561.2 ARF41 0.0007 0.0000 -2.9 0.01 0.0 NM_001661.2 ARF41 0.0007 0.0003 2.2 0.02 0.0 NM_00434.2 NEU1 0.0079 0.0003 2.2 0.01 0.0 NM_015001.2 SHARP 0.0003 0.0001 -2.2 0.01 0.0 NM_020381.1 RAI77 0.0003 0.0001 -2.4 0.00 0.0 NM_0 | _ | ΑΙΟΠδ | 0.0159 | 0.0016 | -2.2 | 0.02 | 0.01 |
| NM_002014.2 FKBP4 0.0003 0.0000 2.8 0.00 0.00 NM_173173.1 NR4A2 0.0000 0.0000 4.1 0.00 0.0 NM_005252.2 FOS 0.0001 0.0000 -2.5 0.01 0.0 NM_006291.2 TNFAIP2 0.0024 0.0000 -2.8 0.00 0.0 NM_00398.2 NFKB1 0.0007 0.0000 -2.9 0.01 0.0 NM_001661.2 ARF4L 0.0007 0.0003 2.2 0.02 0.0 Nucleoside, nucleotide, and nucleic acid metabolism NM_001434.2 NEU1 0.0006 0.0000 6.2 0.01 0.0 NM_031419.1 MA/L 0.0006 0.0000 3.1 0.00 0.0 NM_03266.5 RBP6 0.0009 0.0000 2.5 0.02 0.0 NM_00388.1 RA17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction VIX2 0.0002 0.000 5.2 <td< td=""><td></td><td>HSPA6</td><td>0 0000</td><td>0 0000</td><td>64 4</td><td>0.01</td><td>0.01</td></td<> | | HSPA6 | 0 0000 | 0 0000 | 64 4 | 0.01 | 0.01 |
| NM_173173.1 NR4A2 0.0000 0.0000 4.1 0.00 0.000 NM_005252.2 FOS 0.0001 0.0000 62.1 0.01 0.0 NM_003998.2 NFKB1 0.0003 0.0000 -2.5 0.01 0.0 NM_172390.1 NFATC1 0.0007 0.0000 -2.8 0.00 0.0 Intracellular protein traffic 0.0007 0.0000 -2.8 0.00 0.0 NM_001661.2 ARF4L 0.0007 0.0000 3.8 0.01 0.0 NM_00434.2 NEU1 0.0079 0.003 2.2 0.02 0.0 Nucleoside, nucleotide, and nucleic acid metabolism 0.00 0.0 NM_01501.2 SHARP 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism and modification 0.00 0.0 NM_020338.1 RA/17 0.0002 0.0001 -2.4 0.00 0.0 | _ | | | | | | 0.01 |
| NM_006291.2 TNFAIP2 0.0024 0.0000 -2.5 0.01 0.0 NM_003998.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.0 NM_172390.1 NFATC1 0.0007 0.0000 -2.9 0.01 0.0 Intracellular protein traffic 0.0079 0.0003 2.2 0.02 0.00 NM_000434.2 NEU1 0.0079 0.0003 2.2 0.02 0.00 Nucleoside, nucleotide, and nucleic acid metabolism 0.000 3.1 0.00 0.00 NM_031419.1 MA/L 0.0003 0.0000 3.1 0.00 0.00 NM_032626.5 RBP6 0.0009 0.0000 2.5 0.02 0.00 Other metabolism and modification 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 <td>NM_173173.1</td> <td>NR4A2</td> <td>0.0000</td> <td>0.0000</td> <td>4.1</td> <td>0.00</td> <td>0.00</td> | NM_173173.1 | NR4A2 | 0.0000 | 0.0000 | 4.1 | 0.00 | 0.00 |
| NM_003998.2 NFKB1 0.0003 0.0000 -2.8 0.00 0.00 NM_172390.1 NFATC1 0.0007 0.0000 -2.9 0.01 0.00 Intracellular protein traffic 0.0003 3.8 0.01 0.0 NM_001661.2 ARF4L 0.00079 0.0003 2.2 0.02 0.0 Nucleoside, nucleotide, and nucleic acid metabolism 0.0006 0.0000 6.2 0.01 0.0 NM_031419.1 MA/L 0.0006 0.0000 6.2 0.01 0.0 NM_032626.5 RBBP6 0.0003 0.0000 2.5 0.02 0.0 Other metabolism 0.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | NM_005252.2 | FOS | 0.0001 | 0.0000 | 62.1 | 0.01 | 0.01 |
| NM_172390.1 NFATC1 0.0007 0.0000 -2.9 0.01 0.00 Intracellular protein traffic NM_001661.2 ARF4L 0.0008 0.0000 3.8 0.01 0.0 NM_000434.2 NEU1 0.0079 0.0003 2.2 0.02 0.0 Nucleoside, nucleotide, and nucleic acid metabolism 0.0000 6.2 0.01 0.0 NM_031419.1 MAIL 0.0006 0.0000 6.2 0.01 0.0 NM_04089.2 DSIPI 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism 0.0029 0.0000 2.5 0.02 0.0 Protein metabolism and modification 0.00 0.0 | _ | | | | | | 0.00 |
| Intracellular protein traffic NM_001661.2 ARF4L 0.0008 0.0000 3.8 0.01 0.0 NM_000434.2 NEU1 0.0079 0.0003 2.2 0.02 0.0 Nucleoside, nucleotide, and nucleic acid metabolism 0.0000 6.2 0.01 0.0 NM_031419.1 MAIL 0.0006 0.0000 3.1 0.00 0.0 NM_015001.2 SHARP 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.0 Protein metabolism and modification 0.0 0.0 NM_020338.1 RAI17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction 0.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | - | | | | | | 0.00 |
| NM_001661.2 ARF4L 0.0008 0.0000 3.8 0.01 0.0000 NM_000434.2 NEU1 0.0079 0.0003 2.2 0.02 0.00 Nucleoside, nucleotide, and nucleic acid metabolism 0.0000 6.2 0.01 0.0 NM_031419.1 MAIL 0.0006 0.0000 6.2 0.01 0.0 NM_04089.2 DSIPI 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.0 Protein metabolism and modification 0.00 0.0001 -2.4 0.00 0.0 Signal transduction 0.00 0.0 | | NFATUT | 0.0007 | 0.0000 | -2.9 | 0.01 | 0.00 |
| NM_000434.2 NEU1 0.0079 0.0003 2.2 0.02 0.00 Nucleoside, nucleotide, and nucleic acid metabolism NM_031419.1 MA/L 0.0006 0.0000 6.2 0.01 0.0 NM_004089.2 DSIPI 0.0003 0.0000 3.1 0.00 0.0 NM_015001.2 SHARP 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.0 Protein metabolism and modification 0.00 0.000 2.5 0.00 0.0 Signal transduction 0.00 0.0 | | ARF4I | 0 0008 | 0 0000 | 3.8 | 0.01 | 0.00 |
| Nucleoside, nucleotide, and nucleic acid metabolism NM_031419.1 MA/L 0.0006 0.0000 6.2 0.01 0.0 NM_004089.2 DSIPI 0.0038 0.0000 3.1 0.00 0.0 NM_015001.2 SHARP 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism 0.000 2.5 0.02 0.0 Protein metabolism and modification 0.000 6.6 0.01 0.0 NM_020383.1 RAI17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction 0.000 5.2 0.01 0.0 NM_021955.2 EDN1 0.0003 0.0000 5.2 0.01 0.0 NM_02158.3 C20orf97 0.013 0.0000 3.7 0.0 0.0 NM_02158.3 RAD 0.0003 0.0000 3.7 0.00 0.0 <td< td=""><td>_</td><td></td><td></td><td></td><td></td><td></td><td>0.00</td></td<> | _ | | | | | | 0.00 |
| NM_004089.2 DSIPI 0.0003 0.0000 3.1 0.00 0.0 NM_015001.2 SHARP 0.0038 0.0001 -2.2 0.01 0.0 Other metabolism | Nucleoside, nucleotide, an | | | | | | |
| NM_015001.2 SHARP 0.0038 0.0001 -2.2 0.01 0.00 Other metabolism NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.00 Protein metabolism and modification NM_152461.1 FLJ30999 0.0002 0.0000 6.6 0.01 0.0 NM_02338.1 RAI17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction NM_001955.2 EDN1 0.0025 0.0001 2.2 0.01 0.0 NM_006622.1 PLK2 0.0025 0.0001 2.2 0.01 0.0 NM_021158.3 C20orf97 0.0013 0.0000 3.7 0.01 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_020529.1 NFKBIA 0.0000 3.7 0.00 0.0 0.0 NM_016084.3 RASD1 0.0002 <td></td> <td></td> <td></td> <td>0.0000</td> <td></td> <td></td> <td>0.01</td> | | | | 0.0000 | | | 0.01 |
| Other metabolism NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.0 Protein metabolism and modification 0.0000 6.6 0.01 0.0 NM_152461.1 FLJ30999 0.0002 0.0000 6.6 0.01 0.0 Signal transduction 0.002 0.0001 -2.4 0.00 0.0 Signal transduction 0.00 0.00 0.0 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>0.01</td></td<> | | | | | | | 0.01 |
| NM_032626.5 RBBP6 0.0009 0.0000 2.5 0.02 0.00 Protein metabolism and modification 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 | _ | SHARP | 0.0038 | 0.0001 | -2.2 | 0.01 | 0.01 |
| Protein metabolism and modification View NM_152461.1 FLJ30999 0.0002 0.0000 6.6 0.01 0.0 NM_020338.1 RAI17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction 0.0000 5.2 0.01 0.0 NM_006622.1 PLK2 0.0025 0.0001 2.2 0.01 0.0 NM_025195.2 C8FW 0.0003 0.0000 4.0 0.00 0.0 NM_021158.3 C20orf97 0.013 0.0000 3.7 0.01 0.0 NM_024165.1 RRAD 0.0003 0.0000 3.7 0.00 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_020529.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0002 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 | | DDDDG | 0 0000 | 0.0000 | 25 | 0.02 | 0.00 |
| NM_152461.1 FLJ30999 0.0002 0.0000 6.6 0.01 0.0 NM_020338.1 RAI17 0.0040 0.0001 -2.4 0.00 0.0 Signal transduction 0.0000 5.2 0.01 0.0 NM_001955.2 EDN1 0.0003 0.0000 5.2 0.01 0.0 NM_025195.2 CBFW 0.0003 0.0000 4.0 0.00 0.0 NM_025195.2 CBFW 0.0013 0.0000 4.0 0.00 0.0 NM_021158.3 C20orf97 0.013 0.0000 3.7 0.01 0.0 NM_024155.1 RRAD 0.0003 0.0000 3.7 0.00 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_016084.3 RASD1 0.0002 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 0.0011 0.0002 -2.6 0.02 | - | | 0.0009 | 0.0000 | 2.0 | 0.02 | 0.00 |
| NM_020338.1 RAI17 0.0040 0.0001 -2.4 0.00 0.00 Signal transduction 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00< | | | 0.0002 | 0.0000 | 6.6 | 0.01 | 0.01 |
| NM_001955.2 EDN1 0.0003 0.0000 5.2 0.01 0.0 NM_006622.1 PLK2 0.0025 0.0001 2.2 0.01 0.0 NM_025195.2 C8FW 0.0003 0.0000 4.0 0.00 0.0 NM_021158.3 C20orf97 0.0013 0.0000 3.7 0.01 0.0 NM_024165.1 RRAD 0.0003 0.0000 3.7 0.01 0.0 NM_02529.1 NFKBIA 0.006 0.0000 3.7 0.00 0.0 NM_02928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0012 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 0.0011 0.0002 -2.6 0.02 0.0 | _ | | | | | | 0.00 |
| NM_006622.1 PLK2 0.0025 0.0001 2.2 0.01 0.0 NM_025195.2 C8FW 0.0003 0.0000 4.0 0.00 0.0 NM_021158.3 C20orf97 0.0013 0.0000 3.7 0.01 0.0 NM_004165.1 RRAD 0.0003 0.0000 4.4 0.01 0.0 NM_025259.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.002 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 0.0011 0.0002 -2.6 0.02 0.0 | Signal transduction | | | | | | |
| NM_025195.2 C8FW 0.0003 0.0000 4.0 0.00 0.0 NM_021158.3 C20orf97 0.0013 0.0000 3.7 0.01 0.0 NM_004165.1 RRAD 0.0003 0.0000 4.4 0.01 0.0 NM_02529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0012 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | | | | | | | 0.00 |
| NM_021158.3 C20orf97 0.0013 0.0000 3.7 0.01 0.0 NM_004165.1 RRAD 0.0003 0.0000 4.4 0.01 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0011 0.0000 3.0 0.01 0.0 NM_01511.1 CXCL1 0.0011 0.0002 -2.6 0.02 0.0 | | | | | | | 0.01 |
| NM_004165.1 RRAD 0.0003 0.0000 4.4 0.01 0.0 NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.002 0.0000 4.9 0.00 0.0 NM_01511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | | | | | | | 0.01 |
| NM_020529.1 NFKBIA 0.0006 0.0000 3.7 0.00 0.0 NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0002 0.0000 4.9 0.00 0.0 NM_001511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | _ | | | | | | |
| NM_002928.2 RGS16 0.0010 0.0000 2.5 0.02 0.0 NM_016084.3 RASD1 0.0002 0.0000 4.9 0.00 0.0 NM_001511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | _ | | | | | | 0.00 |
| NM_016084.3 RASD1 0.0002 0.0000 4.9 0.00 0.0 NM_001511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | _ | | | | | | 0.00 |
| NM_001511.1 CXCL1 0.0011 0.0000 3.0 0.01 0.0 NM_170662.2 CBLB 0.0054 0.0002 -2.6 0.02 0.0 | — | | | | | | 0.01 |
| | | | | | | | 0.01 |
| Transport | _ | CBLB | 0.0054 | 0.0002 | -2.6 | 0.02 | 0.00 |
| | Transport | | | | | _ | |
| | | | | | | | 0.01 |
| <u>MGC4504</u> 0.0044 0.0001 2.2 0.00 0.0 ^a From GenBank (NCBI 2006b). ^b CV is coefficient of variation, which represents the ratio of the SD to the mean. | | | | | | | 0.00 |

^aFrom GenBank (NCBI 2006b). ^bCV is coefficient of variation, which represents the ratio of the SD to the mean.

Microarray technology for profiling global gene expression has evolved and provides a powerful tool in the development of biomarkers and the effects of exposure. A critical hypothesis in this research area is that the resulting transcript profile can provide both reliable advance information on possible toxic outcomes and mechanistic insight into the toxicity itself. Although there is a recent report regarding the gene transcription profiling of formaldehyde-exposed rats (Sul et al. 2007), this is the first investigation of the effects of FA on the transcriptomal profile in humans using this technology. Our results demonstrate that in a paired sampling study design (control and FA-exposed individuals), small changes in the gene expression profile can be measured from whole-blood total RNA using a combination of microarray hybridization and Q-PCR. It offers many advantages, including the availability of a huge number of candidate markers, the accuracy of the data, and the cost-effectiveness of the experiments. This strategy is efficient in narrowing the number of candidates and identifying biomarkers in human studies. Our results show that this method is suitable for assessing biomarkers of toxic effects and, more specifically, that it can be used to analyze biomarkers of FA exposure.

A global analysis of more than 23,000 well-characterized human genes was performed using an Illumina bead chip and FAexposed Hs 680.Tr. When the microarray data from the control and FA-treated cells were analyzed by ANOVA, about 6.0% of the genes showed statistically significant changes in expression. To control for the increased chance of discovering false positives we used the Benjamini-Hochberg multiple testing correction method (FDR < 0.05). Genes for Q-PCR confirmation were selected from 54 differentially expressed genes based on the fold change in expression

| Table 3. Q | -PCR validation | of | selected | genes | from |
|------------|-----------------|----|----------|-------|------|
| microarray | / data. | | | | |

| Gene | Microarray | Q-PCR |
|----------|----------------|----------------|
| PLK2 | 2.2 ± 0.1 | 1.8 ± 0.4 |
| SGK | 3.9 ± 0.2 | 3.4 ± 1.5 |
| SE20-4 | 2.5 ± 0.2 | 2.4 ± 0.2 |
| BHLHB2 | 2.8 ± 0.1 | 4.2 ± 0.2 |
| CCNL1 | 3.1 ± 0.2 | 2.6 ± 0.4 |
| C8FW | 4.0 ± 0.2 | 2.3 ± 0.2 |
| HES1 | 8.9 ± 0.9 | 1.7 ± 0.4 |
| FOSB | 52 ± 1.8 | 2.6 ± 0.1 |
| DUSP2 | 17 ± 0.0 | 1.7 ± 0.1 |
| PPP1R15A | 4.6 ± 0.1 | 0.9 ± 0.2 |
| NFKB1A | 3.7 ± 0.3 | 0.9 ± 0.2 |
| NEU1 | 2.2 ± 0.1 | 1.1 ± 0.1 |
| DDAH1 | -2.2 ± 0.0 | -1.8 ± 0.1 |
| NFATC1 | -2.9 ± 0.0 | -1.8 ± 0.2 |
| NVKB1 | -2.8 ± 0.0 | -5.2 ± 0.8 |

Data are mean \pm SD of three independent measurements, which represent fold change on log_2 scale compared with data obtained from control group.

and the proposed functions of the genes. As expected, the results obtained from microarray experiments correlated well with Q-PCR, although there were some examples that did not match. One possible explanation is that the Illumina probes for the well-correlated genes are at the 3' end of transcripts, whereas the probes for the genes that do not match span exons further upstream (Forrest et al. 2005).

In the first set of people studied (129 subjects), the urinary TZCA concentration in the exposed group was nearly double that in the control group (p < 0.003). Although we cannot exclude the possibility that factors other than FA exposure may contribute to TZCA formation, the majority of TZCA excreted can be ascribed to FA exposure.

However, in the second experiment in which only 22 human samples were analyzed, we found no statistical difference between the control and exposure groups. This was probably because of the small sample size and other potential sources of FA exposure such as foods, disinfectants, preservatives, and cosmetics (Nava and Nakanishi 2005; Oyama et al. 2002). Therefore, we reclassified the subjects into three groups according to urinary TZCA concentration, namely, low-, intermediate-, and high-TZCA groups. No one from the old apartment complex was classified into the high-TZCA group (Table 5). Using this classification, we found remarkable consistency between the experimental in vitro microarray data and Q-PCR results obtained from subjects from real environmental exposure. Among the 9 genes analyzed in human blood samples, the expression of 6 genes, namely, BHLHB2, CCNL1, SE20-4, C8FW,

PLK2, and *SGK1*, was significantly higher in the high-TZCA group than in the low-TZCA group. For *BHLHB2* and *SGK1*, the increase was also significant in the intermediate-TZCA group. These results indicate that the combination of *in vitro* microarray hybridization followed by Q-PCR validation is a good tool for discovering genes that may act as biomarkers, as well as for investigating the early stages of environmental diseases.

Serum- and glucocorticoid-induced protein kinase 1 (SGK1) was originally identified as an immediate early gene transcriptionally induced by serum or glucocorticoids in tumor cells (Webster et al. 1993a, 1993b). However, its expression is ubiquitous and is controlled by many cellular stresses. In inflammatory and immune reactions, SGK1 expression is stimulated by proinflammatory mediators, including tumor necrosis factor- α (TNF- α) and lipopolysaccharide (Cowling and Birnboim 2000). TNF- α levels are reported to increase in response to FA exposure (Bianchi et al. 2004). We found that FA exposure activated SGK1 transcription, demonstrating that SGK1 is useful as an early indicator of FA exposure.

Basic helix–loop–helix protein (*bHLH*), also known as DEC1, STRA13, Stra14, and SHARP-2, is involved in chondrocyte and neuronal differentiation (Boudjelal et al. 1997; Shen et al. 1997). Human DEC1 is highly expressed in various tumor types but not in the adjacent normal tissues, demonstrating the significance of this protein as an oncogenic marker. Overexpression of bHLH in HEK-293 cells causes the inhibition of proliferation, blocks apoptosis induced by serum deprivation, and selectively inhibits the activation of procaspases (Li et al. 2002).

| Table 4. Demographics of study subjects in the first experiment |
|---|
|---|

| | Reside | ents in | |
|--------------------------------------|-------------------|-------------------|-----------------|
| Characteristics | Old apartment | New apartment | <i>p</i> -Value |
| No. of subjects | 20 | 109 | |
| No. of smokers (%) | 2 (10) | 27 (24.8) | |
| Age (years) | 21.5 ± 2.1 | 28.6 ± 16.4 | 0.0532 |
| Duration of residence (days) | 87.0 ± 3.6 | 41.2 ± 13.0 | < 0.001 |
| TZCA concentration (mg/g creatinine) | 0.097 ± 0.040 | 0.180 ± 0.121 | < 0.003 |

Data are expressed as mean ± SD.

| Table 5. Demographics of study subjects in the second experiment |
|--|
|--|

| Group of subjects (TZCA concentration, mg/g creatinine) | | | | | |
|---|--|--|-----------------------------|------------------------------|--|
| Characteristics | Low TZCA ^{a} (TZCA \leq 0.053) | Intermediate TZCA ($0.053 < TZCA \le 0.141$) | High TZCA (TZCA > 0.141) | <i>p</i> -Value ^b | |
| No. of subjects | 6 | 10 | 6 | | |
| No. of smokers | _ | | _ | | |
| Age of subjects (years \pm SD) | 35.2 ± 13.4 (~ 15–52) | 22.3 ± 11.1 (~ 10-49) | 25.7 ± 16.3 (~ 12–42) | 0.194 | |
| No. of new apartment residents | 5 | 4 | 6 | | |
| No. of old apartment residents | 1 | 6 | 0 | | |
| Mean TZCA concentration | 0.033 ± 0.020 | 0.090 ± 0.032 | 0.219 ± 0.095 | < 0.0001 | |

^aAll the subjects were separated into low-, intermediate-, and high-exposure groups on the basis of urinary TZCA concentration. Low- and high-exposure groups represent lower 25% and higher 25% in TZCA concentration of all the subjects, respectively. ^bData are analyzed by one-way ANOVA and expressed as mean ± SD. Polo-like kinase-2 (*PLK2*) is a member of the "polo" family of serine/threonine protein kinases that play a role in cell division. PLK2 inhibits apoptosis by blocking cell cycle progression, thus maintaining genomic integrity. The activation of PLK2 arrests the cell cycle in the G_2/M phase, and the loss of PLK2 increases apoptosis in cells (Burns et al. 2003). Ectopic expression of TRIB1 (also known as *C8FW*) in HeLa cells increased the extent and rate of ERK phosphorylation in response to PMA, indicating that TR1B1 plays a role in the mitogen-activated protein kinase (MAPK)

signaling pathway (Kiss-Toth et al. 2004). MAPK activation is an early event in the response to a wide range of stimuli that induces a wide variety of biological effects. For example, MAPK activation is involved in the inhibition of apoptosis, invasion, and metastasis of cancer cells (Bhowmick et al. 2001; Janda et al. 2002). According to Feick et al. (2006), the exposure of intestinal epithelial cells to low doses of FA leads to the phosphorylation of ERK-1/2 and p38 MAP kinase. Our results demonstrate that FA exposure in both experimental and environmental settings caused transcriptional




Figure 3. Expression of selected genes (mean \pm SE) after formaldehyde exposure. Subjects were grouped according to the urinary concentration of TZCA, measured using gas chromatography and mass spectrometry as described in "Materials and Methods." The expression level of each gene was assessed by Q-PCR and normalized against β -actin.

Statistically significant differences compared with the low-TZCA group are indicated as *p < 0.05. **p < 0.01.




Figure 4. Correlation between the urinary concentration of TZCA and the magnitude of expression for each gene, with linear regression lines, Pearson's correlation coefficient, and significance. F = 0.405; p = 0.031

activation of *C8FW*. Considering the antiapoptotic activity of FA in HT-29 human colon carcinoma cells (Tyihak et al. 2001), increased expression of *BHLHB2*, *PLK2*, and *C8FW* mRNA after FA exposure may play important roles in FA-induced inhibition of apoptosis and carcinogenesis.

Cutaneous T-cell lymphoma-associated tumor antigen (SE20-4), also known as differentially expressed nucleolar transforming growth factor (TGF)-\beta1 target protein (DENTT), is a member of the TSPY/TSPYlike/SET/NAP-1 superfamily whose mRNA is overexpressed in TGF-B1-induced human lung cancer cells (Ozbun et al. 2001). Cyclin L1 (CCNL1) is a novel cyclin that plays roles in cell cycle entry and is involved in the regulation of RNA polymerase II transcription. Transcriptional analysis in 20 head and neck squamous cell carcinomas showed the overexpression of CCNL1 in all the tissues (Redon et al. 2002). The upregulation of these two cancer-related genes in the FA-exposed subjects indicates that they may serve as early biomarkers for FA-induced carcinogenesis.

In conclusion, we identified 54 FAresponsive genes in human tracheal fibroblasts. Among them 6 genes were upregulated in the high urinary TZCA subjects. Although blood cells are not representative of all target cells for FA toxicity, dose-dependent increases in the expression of a subset of 6 genes may provide insight into inflammation and carcinogenesis after FA exposure. Further studies with larger sample sizes are needed to define the dose-response relationship between FA exposure and gene expression at the population level.

REFERENCES

- Al-Nabulsi I, Wheeler KT. 1999. Radiation-induced DNA damage in tumors and normal tissues. V: Influence of pH and nutrient depletion on the formation of DNA-protein crosslinks in irradiated partially and fully hypoxic tumor cells. Radiat Res 151:188–194.
- Alexandersson R, Hedenstierna G. 1988. Respiratory hazards associated with exposure to formaldehyde and solvents in acid-curing paints. Arch Environ Health 43:222–227.
- Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. 2001. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12:27–36.
- Bianchi M, Martucci C, Biella G, Ferrario P, Sacerdote P. 2004. Increased substance P and tumor necrosis factor-alpha level in the paws following formalin injection in rat tail. Brain Res 1019:255–258.
- Boudjelal M, Taneja R, Matsubara S, Bouillet P, Dolle P, Chambon P. 1997. Overexpression of Stra13, a novel retinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of P19 cells. Genes Dev 11:2052–2065.
- Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23:556–5571.
- Chakrabarti SK, Bai C, Subramanian KS. 2001. DNA-protein crosslinks induced by nickel compounds in isolated rat lymphocytes: role of reactive oxygen species and specific amino acids. Toxicol Appl Pharmacol 170:153–165.

- Cowling RT, Birnboim HC. 2000. Expression of serum- and glucocorticoid-regulated kinase (sgk) mRNA is up-regulated by GM-CSF and other proinflammatory mediators in human granulocytes. J Leukoc Biol 67:240–248.
- Dallas CE, Scott MJ, Ward JB, Jr., Theiss JC. 1992. Cytogenetic analysis of pulmonary lavage and bone marrow cells of rats after repeated formaldehyde inhalation. J Appl Toxicol 12:199–203.
- Feick P, Haas SR, Singer MV, Bocker U. 2006. Low-dose exposure of intestinal epithelial cells to formaldehyde results in MAP kinase activation and molecular alteration of the focal adhesion protein paxillin. Toxicology 219:60–72.
- Forrest MS, Lan Q, Hubbard AE, Zhang L, Vermeulen R, Zhao X, et al. 2005. Discovery of novel biomarkers by microarray analysis of peripheral blood mononuclear cell gene expression in benzene-exposed workers 4. Environ Health Perspect 113:801–807.
- Gene Map Annotator and Pathway Profiler. 2007. Home Page. Available: http:// www.genmapp.org [accessed 26 May 2007].
- Gottschling LM, Beaulieu HJ, Melvin WW. 1984. Monitoring of formic acid in urine of humans exposed to low levels of formaldehyde. Am Ind Hyg Assoc J 45:19–23.
- Heck HD, Casanova-Schmitz M, Dodd PB, Schachter EN, Witek TJ, Tosun T. 1985. Formaldehyde (CH2O) concentrations in the blood of humans and Fischer-344 rats exposed to CH₂O under controlled conditions. Am Ind Hyg Assoc J 46:1–3.
- IARC (International Agency for Research on Cancer). 2004. Overall Evaluations of Carcinogenicity to Humans. Group 1: Carcinogenic to Humans. Available: http://monographs. iarc.fr/ENG/Classification/crthgr01.php [accessed 16 February 2007].
- Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. 2002. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156:299–313.
- Kane LE, Alarie Y. 1977. Sensory irritation to formaldehyde and acrolein during single and repeated exposures in mice. Am Ind Hyg Assoc J 38:509–522.
- Kerns WD, Pavkov KL, Donofrio DJ, Gralla EJ, Swenberg JA. 1983. Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res 43:4382–4392.
- Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. 2004. Human tribbles, a protein family controlling

mitogen-activated protein kinase cascades. J Biol Chem 279:42703–42708.

- Kuhn K, Baker SC, Chudin E, Lieu MH, Oeser S, Bennett H, et al. 2004. A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res 14:2347–2356.
- Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D, et al. 2002. Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem J 367:413–422.
- Liteplo RG, Meek ME. 2003. Inhaled formaldehyde: exposure estimation, hazard characterization, and exposure-response analysis. J Toxicol Environ Health B Crit Rev 6:85–114.
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-∆∆CT} method. Methods 25:402–408.
- Migliore L, Ventura L, Barale R, Loprieno N, Castellino S, Pulci R. 1989. Micronuclei and nuclear anomalies induced in the gastro-intestinal epithelium of rats treated with formaldehyde. Mutagenesis 4:327–334.
- NCBI. 2006a. Entrez Nucleotide Database. Bethesda, MD:National Center for Biotechnology Information. Available: http://www. ncbi.nlm.nih.gov/sites/entrez/ [accessed 18 September 2006].
- NCBI. 2006b. GenBank. Bethesda, MD:National Center for Biotechnology Information. Available: http://www.ncbi.nlm. nih.gov/sites/gquery?term=genbank [accessed August 2006].
- Naya M, Nakanishi J. 2005. Risk assessment of formaldehyde for the general population in Japan. Regul Toxicol Pharmacol 43:232–248.
- Oyama Y, Sakai H, Arata T, Okano Y, Akaike N, Sakai K, et al. 2002. Cytotoxic effects of methanol, formaldehyde, and formate on dissociated rat thymocytes: a possibility of aspartame toxicity. Cell Biol Toxicol 18:43–50.
- Ozbun LL, You L, Kiang S, Angdisen J, Martinez A, Jakowlew SB. 2001. Identification of differentially expressed nucleolar TGF-beta1 target (DENTT) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily. Genomics 73:179–193.
- PANTHER Classification System. 2007. Home Page. Available: http:// www.pantherdb.org [accessed 26 May 2007].
- Ratner S, Clarke HT. 1937. The action of formaldehyde upon cysteine. J Am Chem Soc 59:200–296.
- Redon R, Hussenet T, Bour G, Caulee K, Jost B, Muller D, et al.

2002. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res 62:6211–6217.

- Shaham J, Bomstein Y, Gurvich R, Rashkovsky M, Kaufman Z. 2003. DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde. Occup Environ Med 60:403–409.
- Shen M, Kawamoto T, Yan W, Nakamasu K, Tamagami M, Koyano Y, et al. 1997. Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun 236:294–298.
- Shin HS, Ahn HS, Lee BH. In press. Determination of thiazolidine-4-carboxylates in urine by chloroformate derivatization and gas chromatography-electron impact mass spectrometry. J Mass Spectrom.
- Speit G, Merk O. 2002. Evaluation of mutagenic effects of formaldehyde in vitro: detection of crosslinks and mutations in mouse lymphoma cells. Mutagenesis 17:183–187.
- Speit G, Schmid D, Frohler-Keller M, Lang I, Triebig G. 2007. Assessment of local genotoxic effects of formaldehyde in humans measured by the micronucleus test with exfoliated buccal mucosa cells. Mutat Res 627:129–135.
- Speit G, Schutz P, Merk 0. 2000. Induction and repair of formaldehyde-induced DNA-protein crosslinks in repairdeficient human cell lines. Mutagenesis 15:85–90.
- Sul D, Kim H, Oh E, Phark S, Cho E, Choi S, et al. 2007. Gene expression profiling in lung tissues from rats exposed to formaldehyde. Arch Toxicol 81(8):589–597doi:10.1007/ s00204-007-0182-9 [Online 7 February 2007].
- Takafuji S, Nakagawa T. 2000. Air pollution and allergy. J Investig Allergol Clin Immunol 10:5–10.
- Tyihak E, Bocsi J, Timar F, Racz G, Szende B. 2001. Formaldehyde promotes and inhibits the proliferation of cultured tumour and endothelial cells. Cell Prolif 34:135–141.
- Webster MK, Goya L, Firestone GL. 1993a. Immediate-early transcriptional regulation and rapid mRNA turnover of a putative serine/threonine protein kinase. J Biol Chem 268:11482–11485.
- Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL. 1993b. Characterization of sgk, a novel member of the serine/ threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 13:2031–2040.